This clinical trial is focused on studying a type of kidney cancer known as advanced or metastatic clear cell renal cell carcinoma. This is a condition where cancer cells form in the lining of the tubules in the kidney and have spread to other parts of the body. The study is investigating a treatment called nivolumab, which is a medication that helps the immune system fight cancer. Nivolumab is being tested in two forms: one that is given through a vein, known as intravenous nivolumab, and another that is injected under the skin, called subcutaneous nivolumab. The subcutaneous form is also referred to by its code name, BMS-986298.

The purpose of this study is to compare the effectiveness of the subcutaneous form of nivolumab to the intravenous form in patients who have already received other treatments for their cancer. Participants in the study will be randomly assigned to receive either the subcutaneous or intravenous form of nivolumab. The study will monitor how the medication is processed in the body and its effects on the cancer over time. Some participants may receive a placebo, which is a substance with no active medication, to help compare the results.

Throughout the study, participants will have regular check-ups to monitor their health and the progress of their cancer. The study aims to provide valuable information on whether the subcutaneous form of nivolumab is as effective as the intravenous form, potentially offering a more convenient treatment option for patients with advanced kidney cancer. The study is expected to continue for several years to gather comprehensive data on the treatment’s long-term effects and safety.